Polish Society of
Endocrinology

30.12.2019

Łukasz Bułdak, Bogdan Marek, Dariusz Kajdaniuk, Agata Urbanek, Szymon Janyga, Aleksandra Bołdys, Marcin Basiak, Mateusz Maligłówka, Bogusław Okopień


Abstract
Cardiovascular diseases are among the leading causes of increased morbidity and mortality in developed and developing countries. One of the most important risk factors responsible for atherosclerosis and subsequent cardiovascular diseases is hyperlipidaemia. Currently, hyperlipidaemias are divided into several clinical entities. The greatest risk is associated with hypercholesterolaemia. As a result, modern guidelines for the treatment and prevention of atherosclerosis focus predominantly on the reduction of LDL-cholesterol. Hypertriglyceridaemia and atherogenic dyslipidaemia, which are responsible for a less significant increase in the cardiovascular risk, are nowadays secondary targets of the treatment.

During the work-up for hyperlipidaemia one of the essential actions is the exclusion of secondary causes of the lipid abnormalities. Those include, among others, endocrine diseases, diabetes, drugs, nephrotic syndrome, and pregnancy. Data regarding the impact of endocrine disease and diabetes on the lipid profile are scattered. In this review, the authors aimed to perform a thorough analysis of the available publications regarding the topic and the preparation of a comprehensive review dealing with the incidence, clinical features, and the therapy of hyperlipidaemias in patients with endocrine disease. 

Keywords: hypercholesterolaemia; hypertriglyceridaemia; hyperlipidaemia; endocrine disease; diabetes

Full publication in Endokrynologia Polskia »